Key Takeaways
- Forxiga (dapagliflozin) is a fully approved SGLT2 inhibitor spanning three connected indications in the UK, EU and US: type 2 diabetes, symptomatic chronic heart failure across the ejection-fraction range, and chronic kidney disease.
- AstraZeneca reported FY2025 Farxiga/Forxiga total revenue of $8,405 million within its CVRM therapy area, with growth attributed to the heart-failure and CKD indications rather than diabetes alone.
- The dapagliflozin base compound patent has expired (2023 UK/EU; around April 2026 US) and generic versions are now available across all three regions, creating material loss-of-exclusivity pressure.
- The UK Court of Appeal upheld invalidity of AstraZeneca's dapagliflozin patent and SPCs in July 2025, though later method-of-use patents for heart failure and CKD carry reported expiries into 2039-2041.
Empagliflozin remains the closest cardiorenal competitor, and generic dapagliflozin is now itself a competitive and pricing pressure; future commercial performance is not guaranteed.
Introduction
AstraZeneca plc (LSE:AZN) is pursuing broader cardiorenal growth by positioning its dapagliflozin-based medicine Forxiga (US brand Farxiga) at the intersection of heart, kidney and metabolic disease. The central question for investors is whether that strategy can sustain demand now that the medicine's core patent protection has lapsed and generics have entered.
Forxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It is approved in the UK, EU and US across three connected indications: type 2 diabetes, symptomatic chronic heart failure and chronic kidney disease. AstraZeneca reported FY2025 Farxiga total revenue of $8,405 million within its Cardiovascular, Renal and Metabolic (CVRM) therapy area, with growth attributed to the heart-failure and kidney indications.
The strategic logic rests on overlapping patient populations and supportive clinical guidelines. The principal risk is generic erosion, because base-patent protection has expired and generic dapagliflozin is now available across the UK, EU and US. Future commercial outcomes are not guaranteed.
Why is cardiorenal medicine strategically important?
Cardiovascular, renal and metabolic conditions frequently occur together in the same patient. A person with type 2 diabetes may also develop chronic kidney disease and heart failure, and each condition can accelerate the others. Treating these as a connected system, rather than in isolation, is the strategic idea behind AstraZeneca's CVRM therapy area.
Forxiga sits at the centre of that approach. Its mechanism, inhibiting SGLT2 in the kidney's proximal tubule, reduces glucose reabsorption but also produces natriuretic and haemodynamic effects. According to approved product information, these effects underpin cardiovascular and renal benefits that are considered independent of glucose lowering.
For AstraZeneca, one molecule addressing several linked conditions can broaden the eligible patient base and align with how cardiologists, nephrologists and diabetologists increasingly co-manage patients. This concentration also creates dependency: AstraZeneca lists revenue concentration within CVRM among its principal risks, so the same breadth that drives scale can amplify exposure if demand shifts.
The franchise is also wholly owned by AstraZeneca, which sharpens the strategic stakes. Dapagliflozin originated in the former Bristol-Myers Squibb and AstraZeneca diabetes alliance, and AstraZeneca acquired full global rights when it bought out Bristol-Myers Squibb's share of that alliance in 2014. As a result, Forxiga is now a direct AstraZeneca asset with no active third-party co-ownership, so both the commercial upside and the loss-of-exclusivity risk sit squarely with the company rather than being shared with a partner.
How broad is Forxiga's approved treatment footprint?
Forxiga's approved footprint spans three indications in the UK and EU. According to the UK Summary of Product Characteristics (emc, revised 24 September 2024), it is indicated in adults and children aged 10 and above for insufficiently controlled type 2 diabetes, in adults for symptomatic chronic heart failure, and in adults for chronic kidney disease. The single heart-failure wording covers the full range of left ventricular ejection fraction.
The EU centralised authorisation, held by AstraZeneca AB and initially granted on 11 November 2012, carries matching indications. The UK marketing authorisation is held by AstraZeneca UK Limited; both companies are subsidiaries of AstraZeneca plc.
In the US, Farxiga is approved for type 2 diabetes (adults and paediatric patients aged 10 and older), heart failure across the full ejection-fraction range, and chronic kidney disease at risk of progression. The US heart-failure indication was originally approved for reduced ejection fraction in 2020 and expanded in May 2023. Investors should not merge indication wording across regions, as approved uses and labelling differ by market.
What could support future demand?
Several factors may support demand, though none guarantees a commercial outcome. The heart-failure and CKD indications address large, chronic populations, and AstraZeneca attributed FY2025 Farxiga growth to these uses rather than diabetes alone. That shift suggests the cardiorenal indications, added later in the product's life, have become meaningful demand drivers.
The staged regulatory history illustrates how the footprint widened over time: EU diabetes approval in 2012, US diabetes approval in 2014, US heart-failure approval in 2020, US CKD approval in 2021, and the US full-ejection-fraction heart-failure expansion in 2023. Each expansion enlarged the eligible patient pool.
Underlying disease prevalence, ageing populations and growing clinical recognition of connected cardiorenal-metabolic risk describe a sizeable addressable market qualitatively. No specific market-size, share or forecast figures are asserted here. Commercial performance will depend on prescribing patterns, reimbursement and competition, including from lower-cost generics.
What is the role of clinical guidelines?
Clinical treatment guidelines strongly influence how widely a medicine class is used. Where professional bodies position SGLT2 inhibitors as a standard option in heart failure or chronic kidney disease, prescribing across the class tends to broaden, which can expand the overall pool of treated patients.
Guidelines generally address a drug class or established indication rather than endorsing a single brand. That distinction matters commercially, because guideline momentum that benefits SGLT2 inhibitors can also benefit competing molecules and, increasingly, generic dapagliflozin. Broader class adoption is therefore not the same as brand-specific advantage.
For AstraZeneca, supportive guidelines may sustain overall volume even as pricing falls after generic entry. Investors may monitor how guideline-driven uptake interacts with substitution toward lower-cost versions, since higher treated volumes do not automatically translate into higher branded revenue.
What generic or patent risks exist?
Loss of exclusivity is the defining commercial risk. The dapagliflozin base compound patent expired in the UK and EU in mid-2023. In the US, the base compound patent expired around 4 April 2026, and multiple generic dapagliflozin products received FDA approval from April 2026.
UK litigation removed downstream protection. The High Court revoked AstraZeneca's dapagliflozin patent and supplementary protection certificates in April 2025, and the Court of Appeal upheld that invalidity on 16 July 2025 ([2025] EWCA Civ 903), clearing UK generic entry. Earlier in the dispute AstraZeneca had obtained an interim injunction against Glenmark in April 2025 to hold the position while the case was decided, but the subsequent rulings removed that protection. Generic dapagliflozin is now available across the UK and EU.
AstraZeneca retains later method-of-use patents tied to the heart-failure and CKD indications, with expiries reported into 2039-2041, and litigation around these remains a risk. These patents may allow the brand to co-exist with generics, but they do not restore base-molecule exclusivity. The reported $8.4 billion revenue base is therefore exposed to erosion, and post-patent commercial expectations should be treated as uncertain rather than assured.
What should investors monitor?
For readers weighing AstraZeneca's cardiorenal strategy, several observable factors may indicate how the Forxiga franchise performs after loss of exclusivity, though none predicts a commercial outcome. The pace of generic erosion is the most direct signal. Because AstraZeneca discloses Farxiga revenue separately in its results, successive reporting periods should show how quickly the reported $8,405 million FY2025 revenue base is affected as generic dapagliflozin spreads across the UK, EU and US.
A second area is the durability of the remaining method-of-use patents tied to the heart-failure and chronic kidney disease indications, whose expiries are reported into 2039-2041. Litigation around these patents remains a risk, and their outcome may determine whether the brand can co-exist alongside generics in its cardiorenal uses rather than competing on price in diabetes alone. Guideline-driven uptake of SGLT2 inhibitors could sustain treated volumes, but investors may weigh that against substitution toward lower-cost versions, since higher volumes do not automatically convert into branded revenue.
Reimbursement decisions are a further signal. Bodies such as the National Institute for Health and Care Excellence (NICE) and the NHS, along with US payers, influence how far low-cost generics displace the brand once they are listed. Finally, revenue concentration within the CVRM therapy area, which AstraZeneca lists among its principal risks, means that shifts in Forxiga demand carry weight for the wider segment. None of these indicators guarantees future performance, and this article does not offer investment advice.
How may competition affect growth?
Forxiga competes within a crowded SGLT2-inhibitor class. Empagliflozin (Jardiance), marketed by Boehringer Ingelheim and Eli Lilly, is regarded as the closest cardiorenal competitor with overlapping heart-failure and kidney positioning. Other class members include canagliflozin (Invokana) from Johnson & Johnson's Janssen, ertugliflozin (Steglatro) from Merck (MSD), sotagliflozin (Inpefa) from Lexicon Pharmaceuticals, and bexagliflozin (Brenzavvy) from TheracosBio, each competing for prescriber attention within the wider metabolic and cardiorenal space.
The most immediate competitive pressure now comes from generic dapagliflozin itself. Manufacturers including Teva, Glenmark, Sandoz, Cipla, Lupin and Aurobindo are among those associated with generic supply, and low-cost entry typically drives price and reimbursement pressure from bodies such as NICE and the NHS, as well as US payers.
AstraZeneca also faces class-wide safety considerations for SGLT2 inhibitors, such as diabetic ketoacidosis and genital or urinary infections, which can affect labelling and uptake. Taken together, competition, pricing pressure and generic substitution mean future Forxiga growth is not guaranteed, and investors may monitor how AstraZeneca defends the franchise through its remaining indication-specific patents and CVRM breadth.






Please wait processing your request...